In UK, most adults under the age of 40 will be given an alternative to the Oxford-AstraZeneca Covid-19 vaccine due to a link with rare blood clots. The country’s medicines safety regulator said there have been 242 clotting cases and 49 deaths, with 28.5 million doses of the vaccine administered.
However, the risk is slightly higher in younger age groups. The risk of a clot is roughly one in 100,000 for people in their 40s, but rises to one in 60,000 for people in their 30s. Two in a million people in their 40s died rising to four per million people in their 30s.
The supply of alternative vaccines, including Pfizer and Moderna, has made the decision possible.